Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 5, 2021

Lilly’s tirzepatide leads to body weight reductions in type 2 diabetes trial

Eli Lilly and Company has reported that results from the SURPASS-2 clinical trial of tirzepatide showed superior A1C and body weight reductions from baseline in adults with type 2 diabetes.

Eli Lilly and Company has reported that results from the SURPASS-2 clinical trial of tirzepatide showed superior A1C and body weight reductions from baseline in adults with type 2 diabetes.

A novel investigational once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, tirzepatide combines the actions of both incretins into a single molecule.

The multi-centre, randomised, parallel, open-label trial analysed the efficacy and safety of tirzepatide as compared with semaglutide in adults with type 2 diabetes inadequately controlled with ≥1500 mg/day metformin alone.

Semaglutide is a GLP-1 receptor agonist for treating type 2 diabetes.

The trial enrolled 1,879 subjects in the US, UK, Argentina, Australia, Brazil, Canada, Israel and Mexico. They were randomised in a 1:1:1:1 ratio to receive either a 5mg, 10mg, or 15mg dose of tirzepatide or a 1mg dose of semaglutide.

Data showed that tirzepatide led to superior A1C and body weight reductions from baseline in all three tested doses versus semaglutide in the participants.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The highest dose of tirzepatide reduced A1C by 2.46% and body weight by 12.4kg, while the lowest dose reduced A1C by 2.09% and body weight by 7.8kg as against semaglutide at 1.86% and 6.2kg.

Furthermore, an A1C of less than 5.7% was achieved by 51% in tirzepatide 15mg arm versus 20% in semaglutide arm.

The overall safety profile of tirzepatide was similar to previously reported ones with the most commonly reported adverse events were gastrointestinal-related.

Lilly Diabetes president Mike Mason said: “Nearly nine in ten people with type 2 diabetes in the US are overweight or have obesity, and we are committed to providing solutions that not only lead to meaningful A1C reductions but also significant weight loss to help meet their needs.

“These striking head-to-head results surpassed our expectations, supporting our belief in the value of all three doses of tirzepatide as potential new treatment options for people living with type 2 diabetes.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU